CD22-CART / Shanghai Unicar - LARVOL DELTA

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (ASH 2025) - P1 | "Among these, 2 patients were treated with commercial products(relmacabtagene autoleucel or axicabtagene ciloleucel), while the remaining 4 participated in IIT. Notably, CD19/CD20 dual-targeted CAR-T cells showed greater expansion than CD19/CD22CAR-T.ConclusionThe CD19/CD22/CD20 multi-targeted CAR-T therapy demonstrated a favorable safety profile andencouraging efficacy in highly refractory NHL patients failing multiple lines of therapy, including thosewith prior CAR-T failure, antigen loss/downregulation. These promising findings warrant furtherinvestigation in expanded cohorts with long-term follow-up."

Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CD19 • CD22 • TP53

Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma (ASH 2025) - P2 | "Sequential CD19/CD22 CAR-T cell therapy following ASCT represents a clinically significantadvancement for R/R LBCL, demonstrating unprecedented survival outcomes with a manageable safetyprofile. This approach may serve as a potential new standard of care for eligible patients. Furthervalidation through larger, multicenter randomized controlled trials with extended follow-up is warrantedto confirm its long-term efficacy and safety."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD22

Chemotherapy-Free Induction with Venetoclax and Azacitidine, Followed By Tandem CD19/CD22 CAR-T Cell Therapy As First-Line Treatment in Newly Diagnosed High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Prospective, Single-Center, Single-Arm, Phase 2 Trial (ASH 2024) - P2 | "The lower incidence and severity of CRS showed a more favorable safety profile than in R/R ALL. These results support a favorable clinical benefit-risk profile of this regimen as a first-line treatment option in newly diagnosed, high-risk Ph-negative ALL patients."

CAR T-Cell Therapy • Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Neutropenia • Oncology • Septic Shock • Thrombocytopenia • CD22 • CDKN2A • CDKN2B • CRLF2 • CSF1R • EBF1 • IKZF1 • KMT2A • MEF2D • PAX5 • PBX1 • TCF3 • TP53 • ZNF384

Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia (ASH 2023) - "A total of 5 patients with severe cytokine release syndrome (Grade ≥ 3) were observed, including 2 patients in the single CD19 CAR-T group, 2 patients in the tandem CD19/CD22 CAR-T group, and 1 patient in the sequential CD19 and CD22 CAR-T group. Of the 23 patients who achieved CR, 4 patients bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) and 3 patients received decitabine (DAC) consolidation.With the median follow-up of 25.5 months (range, 1.1 to 33.5), the 2-year overall survival, leukemia-free survival (LFS) and cumulative incidence of relapse rates were 23.7%, 30.5% and 69.5%, respectively. Multivariate Cox regression analyses showed that a better LFS related to the absence of high-risk cytogenetics and genetic characteristics, DAC combination with fludarabine and cyclophosphamide lymphodepletion regimen, and bridging allo-HSCT or DAC consolidation. Our study showed that the second infusion of tandem CD19/CD22 CAR-T therapy obtains a..."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD22

The Clinical Outcome of Patients with Refractory/Relapsed Lymphoid Blastic Phase of Chronic Myeloid Leukemia Treated with CAR T-Cells Therapy (ASH 2023) - "All patients received lymphodepletion with fludarabine (30 mg/m2 /d) and cyclophosphamide (300 mg/m2 /d) -based conditioning regimens on day −5 to −3...Among them, 8 patients with CML-LBC and 92 ph+ ALL patients received single CD19 CAR T therapy, others received tandem CD19/CD22 CAR T. The baseline characteristics of all patients were shown in Table 1... Worser sustained antitumor efficacy and long-term survival with CAR T-cells therapy in patients with CML-LBC compared to ph+ ALL patients, and ABL kinase region mutation is an independent risk factor for CR and LFS."

CAR T-Cell Therapy • Clinical • Clinical data • IO biomarker • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • CD22

Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients. (PubMed, Leuk Res) - "Our study recommends decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance strategy to improve the survival outcomes of patients with r/r B-ALL."

Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD22

Long-term follow-up of tandem CD19/CD22 CAR T-Cells in r/r B-ALL patients with high-risk features. (PubMed, Am J Hematol) - No abstract available

CAR T-Cell Therapy • Journal • CD22

DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2023) - "Our retrospective study showed that DAC consolidation after CD19/CD22 CAR-T therapy was a novel maintenance strategy to improve the prognosis of r/r B-ALL patients. CAR-T, B cell acute lymphoblastic leukemia, Consolidation, decitabine"

Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD22 • TP53

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory PCNSL Patient. (PubMed, Cancer Res Treat) - "This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies."

Journal • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD22

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? (PubMed, Blood Cancer J) - P1/2 | "Multivariable analysis in CR patients showed that a low frequency of relapse, a low tumor burden, minimal residual disease-negative CR and bridging to transplantation were independently associated with better leukemia-free survival. Our findings suggested that tandem CD19/CD22 CAR T-cell therapy obtains a better response than CD19 CAR T-cell therapy and a similar response to sequential CD19/CD22 CAR T-cell therapy."

CAR T-Cell Therapy • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation • CD19 • CD22

Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients. (PubMed, Exp Hematol Oncol) - "Here, we speculated that decitabine (DAC) in combination with fludarabine and cyclophosphamide (FC) as a lymphodepletion regimen may improve the efficacy of CD19/CD22 CAR T-cell therapy. All adverse events were reversible and manageable. In conclusion, DAC in combination with the FC lymphodepletion regimen may be a new treatment option that can improve the efficacy of CAR T-cell therapy in r/r B-ALL."

CAR T-Cell Therapy • Combination therapy • Journal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22